[Bank of America raises Sino Biopharmaceutical target to HK$5.9
Reiterates buy] Bank of America Securities issued a report stating that Sino Biopharmaceutical (01177.HK) recently announced that a licensing transaction will be implemented, and the company expects the sales proportion of innovative drugs to increase to more than 50% this year and reach 60% by 2027. The growth momentum is driven by the company's "internal research and development + external licensing" dual-engine strategy. In addition, the company recently received approval from the National Medical Products Administration for its Phase III clinical trial of TQC3721 for the treatment of chronic obstructive pulmonary disease (COPD). The bank took TQC3721's revenue forecast into consideration and raised Sino Biopharmaceutical's total revenue forecast for 2027 by 1%; the target price was raised from HK$5.1 to HK$5.9, and the "buy" rating was reiterated because the company's product pipeline is progressing smoothly.
